ATE538199T1 - Ribosomenpräsentations- und mrna- präsentationsverfahren mit selektion hinsichtlich erhöhter stabilität des proteins - Google Patents

Ribosomenpräsentations- und mrna- präsentationsverfahren mit selektion hinsichtlich erhöhter stabilität des proteins

Info

Publication number
ATE538199T1
ATE538199T1 AT06700177T AT06700177T ATE538199T1 AT E538199 T1 ATE538199 T1 AT E538199T1 AT 06700177 T AT06700177 T AT 06700177T AT 06700177 T AT06700177 T AT 06700177T AT E538199 T1 ATE538199 T1 AT E538199T1
Authority
AT
Austria
Prior art keywords
presentation
selection
mrna
protein stability
ribosome
Prior art date
Application number
AT06700177T
Other languages
English (en)
Inventor
Andrew Buchanan
Lutz Jermutus
Original Assignee
Medimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Ltd filed Critical Medimmune Ltd
Application granted granted Critical
Publication of ATE538199T1 publication Critical patent/ATE538199T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1041—Ribosome/Polysome display, e.g. SPERT, ARM
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1062—Isolating an individual clone by screening libraries mRNA-Display, e.g. polypeptide and encoding template are connected covalently

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT06700177T 2005-01-05 2006-01-05 Ribosomenpräsentations- und mrna- präsentationsverfahren mit selektion hinsichtlich erhöhter stabilität des proteins ATE538199T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US64220905P 2005-01-05 2005-01-05
GBGB0500099.7A GB0500099D0 (en) 2005-01-05 2005-01-05 Methods and means relating to protein variants
PCT/GB2006/000002 WO2006072773A1 (en) 2005-01-05 2006-01-05 Ribosome display or mrna display method with selection for increased stability of the protein

Publications (1)

Publication Number Publication Date
ATE538199T1 true ATE538199T1 (de) 2012-01-15

Family

ID=34179181

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06700177T ATE538199T1 (de) 2005-01-05 2006-01-05 Ribosomenpräsentations- und mrna- präsentationsverfahren mit selektion hinsichtlich erhöhter stabilität des proteins

Country Status (11)

Country Link
US (2) US8288123B2 (de)
EP (1) EP1833965B1 (de)
JP (1) JP5154947B2 (de)
CN (1) CN101180393A (de)
AT (1) ATE538199T1 (de)
AU (1) AU2006204424B2 (de)
CA (1) CA2593151C (de)
DK (1) DK1833965T3 (de)
ES (1) ES2379189T3 (de)
GB (2) GB0500099D0 (de)
WO (1) WO2006072773A1 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60332358D1 (de) 2002-09-09 2010-06-10 Hanall Pharmaceutical Co Ltd Protease-resistente modifizierte interferon alpha polypeptide
GB0500099D0 (en) * 2005-01-05 2005-02-09 Cambridge Antibody Tech Methods and means relating to protein variants
WO2008065372A2 (en) * 2006-11-28 2008-06-05 Nautilus Biotech, S.A. Modified erythropoietin polypeptides and uses thereof for treatment
EP1930342B1 (de) * 2006-12-04 2012-01-25 Institut Pasteur Als Gerüst verwendeter OB-Fold zur Entwicklung neuer spezifischer Bindemittel
EP2297197B1 (de) * 2008-05-29 2012-03-07 HanAll Biopharma Co., Ltd. Modifizierte erythropoietin (epo)-polypeptide mit erhöhter proteaseresistenz und pharmazeutische zusammensetzungen daraus
KR20110076906A (ko) * 2008-09-30 2011-07-06 아보트 러보러터리즈 개선된 ｒｎａ 디스플레이 방법
WO2010096594A2 (en) * 2009-02-18 2010-08-26 Wayne State University Method for identifying a subpopulation of mammalian cells with distinctive ribosome translation profiles
MX2013007067A (es) 2010-12-20 2013-11-01 Medimmune Ltd Anticuerpos anti-il-18 y sus usos.
CN103130893A (zh) * 2011-12-05 2013-06-05 中国人民解放军军事医学科学院卫生学环境医学研究所 己烯雌酚单链抗体筛选方法及其用途
SMT202000340T1 (it) 2012-10-15 2020-07-08 Medimmune Ltd Anticorpi contro il beta amiloide
ES2603589T3 (es) * 2012-11-08 2017-02-28 F. Hoffmann-La Roche Ag Ácidos nucleicos que codifican polipéptidos quiméricos para la identificación sistemática de bibliotecas
WO2015120058A2 (en) 2014-02-05 2015-08-13 Molecular Templates, Inc. Methods of screening, selecting, and identifying cytotoxic recombinant polypeptides based on an interim diminution of ribotoxicity
CN115043943A (zh) 2015-05-15 2022-09-13 综合医院公司 拮抗性抗肿瘤坏死因子受体超家族抗体
CN109476695A (zh) * 2016-06-27 2019-03-15 丹娜法伯癌症研究院 用于测定rna翻译速率的方法
US11034951B2 (en) 2017-11-20 2021-06-15 Nantbio, Inc. mRNA display antibody library and methods
US11015188B2 (en) 2017-11-20 2021-05-25 NantBio Inc. MRNA display antibody library and methods
EP3853252A1 (de) 2018-09-18 2021-07-28 Merrimack Pharmaceuticals, Inc. Anti-tnfr2-antikörper und verwendungen davon
KR102736548B1 (ko) * 2019-01-31 2024-12-02 난트바이오 인코포레이티드 Mrna 디스플레이 항체 라이브러리 및 방법
CA3131953A1 (en) 2019-03-01 2020-09-10 Merrimack Pharmaceuticals, Inc. Anti-tnfr2 antibodies and uses thereof
US12247237B2 (en) 2019-04-10 2025-03-11 Novozymes A/S Polypeptide variants

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2563874A1 (en) 2004-04-23 2005-11-03 Cambridge Antibody Technology Limited Erythropoietin protein variants
GB0500099D0 (en) * 2005-01-05 2005-02-09 Cambridge Antibody Tech Methods and means relating to protein variants

Also Published As

Publication number Publication date
GB2422606B (en) 2007-02-21
ES2379189T3 (es) 2012-04-23
CA2593151C (en) 2016-03-15
JP5154947B2 (ja) 2013-02-27
DK1833965T3 (da) 2012-03-26
US20060183200A1 (en) 2006-08-17
AU2006204424B2 (en) 2011-09-08
WO2006072773A1 (en) 2006-07-13
AU2006204424A1 (en) 2006-07-13
CA2593151A1 (en) 2006-07-13
GB0600147D0 (en) 2006-02-15
JP2008526191A (ja) 2008-07-24
US20070298430A1 (en) 2007-12-27
GB2422606A (en) 2006-08-02
EP1833965B1 (de) 2011-12-21
EP1833965A1 (de) 2007-09-19
GB0500099D0 (en) 2005-02-09
CN101180393A (zh) 2008-05-14
US8288123B2 (en) 2012-10-16

Similar Documents

Publication Publication Date Title
ATE538199T1 (de) Ribosomenpräsentations- und mrna- präsentationsverfahren mit selektion hinsichtlich erhöhter stabilität des proteins
AR062069A1 (es) Replegado de proteinas recombinantes
WO2008019123A3 (en) Enzyme sensors, methods for preparing and using such sensors, and methods of detecting protease activity
WO2005121163A3 (en) Isolation of plasma or serum proteins
WO2005118620A3 (en) Methods for preparing internally constraied peptides and peptidomimetics
WO2007064917A3 (en) Methods of preparation of recombinant forms of human beta-amyloid protein and uses of these proteins
BRPI0516356A (pt) terapia à base de levedura para infecções crÈnicas da hepatite c
DK1697523T3 (da) Ekspressionsvektor til antibiotikafri ekspression
CY1112924T1 (el) Κυτταροδιαπερατοι αναστολεις της jnk-σηματοδοτικης πορειας μεταγωγης
DE60313659D1 (de) Borrelidin-derivate und ihre medizinische anwendung
WO2008127457A3 (en) Nucleic acids encoding recombinant protein a
WO2009007913A3 (en) Protein labelling with tags comprising isotope-coded sub-tags and isobaric sub-tags
WO2009139601A3 (en) Method and affinity column for purifying proteins
BRPI0913174A2 (pt) Método para produzir um hidrolisado de proteína de trigo, hidrolisado de proteína de trigo, e, uso de um hidrolisado de proteína de trigo.
WO2008034622A3 (en) A method of detecting and/or quantifying expression of a target protein candidate in a cell, and a method of identifying a target protein of a small molecule modulator
NO20071456L (no) Motorkontrollmodul og fremgangsmate for a bruke denne i motorsystemproduksjon
EP1641813A4 (de) Verfahren zur herstellung von molekülen mit verminderter immunogenität
NZ601647A (en) Variant hhip1 protein and methods and uses thereof
EA200702193A1 (ru) Гликозилирование белков
WO2008115296A3 (en) Modified phage for displaying post-translationally modified proteins and uses thereof
WO2008092030A3 (en) Specific n-terminal labeling of peptides and proteins in complex mixtures
WO2004108749A3 (en) Binding peptides: methods for their generation and use
WO2007063129A3 (en) Insolation of peptides , polypeptides and proteins
BRPI0409557B8 (pt) proteína recombinante inibidora de calicreína, sequência de dna, vetor de expressão, composição farmacêutica, uso da composição farmacêutica, método de produção da proteína recombinanete e kits de diagnóstico
WO2004087883A3 (en) lovE VARIANT REGULATOR MOLECULES